The global oligonucleotide CDMO market is valued at USD 3.11 billion in 2025 and is projected to reach approximately USD ...

Here are four approvals, changes and recalls made by the FDA that are connected to the anesthesia space, as reported by Becker’s so far in 2025.

Completed patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data ...

The layoffs come despite CEO Kevin Conroy telling investors the company had just completed an “unbelievable quarter” for the ...

In an era where chronic diseases are reshaping global health priorities, the diabetic retinopathy market stands out as a ...

Tokyo, Japan and Cambridge, UK, 8 August 2025 - Nxera Pharma ("the Company" or "Nxera"; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second quar ...

Detailed price information for Scholar Rock Holding Corp (SRRK-Q) from The Globe and Mail including charting and trades.

Glucagon injection salesdeclined 25% to $20.6 million in Q2 2025, driven by increased competition and a market shift toward ...

Recent news reports highlight uncertainty about pharmaceutical tariffs, an error-prone AI tool in use at the FDA, and scientific research funding in jeopardy.

Roxadustat advances as a promising oral treatment for anemia in lower-risk myelodysplastic syndromes, targeting high ...

Key Points On July 22, 2025, the U.S. Food and Drug Administration issued a Complete Response Letter for RP1, delaying potential commercialization and revenue. Research and development expenses ...

GAAP revenue beat expectations at $104.6 million in Q2 2025, Revenue reached $104.6 million, representing a 12% increase compared to Q2 2024, while Non-GAAP EPS of $0.07 missed the $0.10 estimate.